Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus chemotherapy in advanced NSCLC
NCT05329025Phase 2Active, not recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in non-small cell lung cancer (NSCLC), sponsored by Qilu Pharmaceutical. Started Jun 2022; status: active, not recruiting.
02
Drugs
QL1706
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05329025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05329025.